Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy

Clinical Trial Progress - Anixa Biosciences' collaborator, Moffitt Cancer Center, received FDA approval for a second dose of CAR-T therapy for a patient showing clinical activity after initial treatment [1] - In the first cohort at the lowest dose, one patient exhibited tumor necrosis, inflammation, and T cell infiltration, with tumor markers initially rising then falling, leading to FDA approval for a second treatment [2] - The Phase I trial is treating recurrent ovarian cancer patients who have failed standard therapies, with six patients treated so far across two cohorts, and dose escalation continuing after confirming safety [3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio including an ovarian cancer immunotherapy program using CER-T technology [4] - The company's vaccine portfolio, developed with Cleveland Clinic, targets triple-negative breast cancer, ovarian cancer, and other intractable cancers by immunizing against "retired" proteins expressed in certain cancers [4] - Anixa partners with renowned research institutions to examine emerging technologies for further development and commercialization [4]